Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?

References

• von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068–77
   PubMed Web of Science ®Google Scholar
• von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602–8
   PubMed Web of Science ®Google Scholar
• Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18: 1921–7
   PubMed Web of Science ®Google Scholar
• Lorusso V, Manzione L, De Vita F, Antimi M, Selvaggi FP, De Lena M. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: A phase II multicenter trial. J Urol 2000; 164: 53–6
   PubMed Web of Science ®Google Scholar
• Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17: 2876–81
   PubMed Web of Science ®Google Scholar
• Parra HS, Cavina R, Latteri F, Sala A, Dambrosio M, Antonelli G. Three-week versus four-week schedule of cisplatin and gemcitabine: Results of a randomized phase II study. Ann Oncol 2002; 13: 1080–6
   PubMed Web of Science ®Google Scholar
• Parra HS, Cavina R, Latteri F, Campagnoli E, Morenghi E, Torri W. Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study. Invest New Drugs 2007; 25: 57–62
   PubMed Web of Science ®Google Scholar
• Burnett AF, Roman LD, Garcia AA, Muderspach LI, Brader KR, Morrow CP. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 2000; 76: 63–6
   PubMed Web of Science ®Google Scholar
• Yau TK, Lee AW, Wong DH, Yeung RM, Chan EW, Ng WT. Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma. Head Neck 2006; 28: 880–7
   PubMed Web of Science ®Google Scholar
• Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol 2006; 24: 379–85
   PubMed Web of Science ®Google Scholar
• Adamo V, Magno C, Spitaleri G, Garipoli C, Maisano C, Alafaci E, et al. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: Longterm follow-up of a 3-week regimen. Oncology 2005; 69: 391–8
   PubMed Web of Science ®Google Scholar
• Huisman C, Giaccone G, van Groeningen CJ, Sutedja G, Postmus PE, Smit EF. Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: A phase II study with emphasis on scheduling. Lung Cancer 2001; 33: 267–75
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee DH, Shin HC, Kwon JH, Jung JY, Kim HJ. A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2006; 54: 57–62
   PubMed Web of Science ®Google Scholar
• Hussain SA, Stocken DD, Riley P, Palmer DH, Peake DR, Geh JI, et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 2004; 91: 844–9
   PubMed Web of Science ®Google Scholar
• WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.
   Google Scholar
• Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol 1988;121–41.
   PubMedGoogle Scholar
• Zatloukal P, Petruzelka L, Zemanova M, Kolek V, Skrickova J, Pesek M. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: A phase III randomized trial. Lung Cancer 2003; 41: 321–31
   PubMed Web of Science ®Google Scholar
• Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 2006; 52: 155–63
   PubMed Web of Science ®Google Scholar
• Flechon A, Fizazi K, Gourgou-Bourgade S, Theodore C, Beuzeboc P, Geoffrois L. Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: Feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers. Anticancer Drugs 2006; 17: 705–8
   PubMed Web of Science ®Google Scholar
• Sengelov L, Kamby C, Geertsen P, Andersen LJ, von der Maase H. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Pharmacol 2000; 46: 357–64
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173–81
   PubMed Web of Science ®Google Scholar